Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic fibrosing alveolitis, is a
distinct form of interstitial lung disease of unknown etiology that is limited to the lung; it is …

… The recommendations detailed below are based on the evidence-based approach outlined
in the introductory section; these recommendations may change if additional and/or new …

… Over the years, this approach has evolved and most … methodological approach; the umbrella
term is “evidence-based … approach in the treatment of idiopathic pulmonary fibrosis. Am J …

… Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease … A
prompt, accurate diagnosis is important to enable patients to receive treatment early in the …

… need to determine an effective medical treatment regimen with clinically significant and
relevant end-points to improve outcome for patients with idiopathic pulmonary fibrosis (IPF) is …

… our prognostic perspective and impact on therapeutic approaches. The advent of next-generation
genome sequencing to collect epigenomic profiles may provide the way forward. …

… for the approval of new therapies rather than the often differing needs of clinical practice [1]. …
will ever be addressed through an evidence-based approach. Moreover, guidelines based …

… , at present, there are no evidence-based therapies for idiopathic pulmonary fibrosis.
Further controlled studies are warranted to improve the evidence base for clinical practice. …

… management of patients with idiopathic pulmonary fibrosis (IPF). Cochrane reviews are
also a highly respected and reliable source of evidence-based … carried forward method of …

… An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary
fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;…